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Myocardial regenerationDespite advances in primary percutaneous interventions (PPCI), management of microvascular obstructions in
reperfused myocardial tissue remains challenging and is a high-risk procedure. This has led to renewed interest
in the coronary venous system as an alternative route of access to themyocardium. This article reviews historical
data describing therapeutic options via cardiac veins as well as discussing the clinical potential and limitations of
a catheter intervention: pressure controlled intermittent coronary sinus occlusion (PICSO). Collected experimen-
tal and clinical information suggest that PICSO also offers the potential for tissue regeneration beyondmyocardial
salvage. Ameta-analysis of observer controlled pICSO application in animal studies showed a dose dependent re-
duction in infarct size of 29.3% (p b 0.001).
Additionally, a 4-fold increase of hemeoxygenase-1 gene expression (p b 0.001) in the center of infarction and a
2.5 fold increase of vascular endothelial growth factor (VEGF) (p b 0.002) in border zones suggest thatmolecular
pathways are initiating structural maintenance. Early clinical evidence conﬁrmed signiﬁcant salvage and event
free survival in patients with acute myocardial infarction and risk reduction for event free survival 5 years
after the acute event (p b 0.0001). This experimental and clinical evidencewas recently corroborated usingmod-
ern PICSO technology in PPCI showing a signiﬁcant reduction of infarct size, when compared tomatched controls
(p b 0.04). PICSO enhances redistribution ofﬂow towards deprived zones, clearingmicrovascular obstruction and
leading to myocardial protection. Beyond salvage, augmentation of molecular regenerative networks suggests a
second mechanism of PICSO involving the activation of vascular cells in cardiac veins, thus enhancing structural
integrity and recovery.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In recent years, the demographics of patients admitted for coronary
interventions and revascularization procedures have changed, and
there is an increasing need for complex high-risk interventional proce-
dures (CHIP). Despite the development of sophisticated reperfusion
strategies and the availability of logistic treatment networks for acute
coronary syndromes (ACS), the management of obstructed myocardial
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. This is an open access article underchallenging. Furthermore, there are large variations in reperfusion
treatment across Europe; a substantial number of ST-elevation myocar-
dial infarction (STEMI) patients in Eastern and Southern Europe are not
receiving any reperfusion therapy [1]. Although mortality from acute
events has decreased, therapies to prevent or attenuate postinfarction
left ventricular remodeling have changed little, leaving an increasing co-
hort of patients at risk of severe heart failure [2]. Current routine thera-
pies in ACS focus on the ischemic/reperfused microcirculation and on
structural regeneration. Despite timely reperfusion, molecular,ium; CSI, coronary sinus interventions: surgical and catheter interventions using the CS as
ent coronary sinus occlusion: time dependent occlusion of the CS to redistributeﬂowwith-
feedback loop; PICSO, pressure controlled intermittent coronary sinus occlusion with au-
quent venous shunt from aorta to coronary sinus; Retroperfusion, Shunting arterial blood
iastole by means of a catheter system in the coronary sinus; SSR, selective synchronized
drainage; Banai stent, interventional method deploying a stent within the great cardiac
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l cardiac arrest; Blastema, a mass of cells capable of growth and regeneration into organs
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circulation persist, as well as areas of structural obstruction, particularly
in the post capillary venules. Therefore there is a need for methods to
further reduce microcirculatory obstruction, an important prognostic
factor for morbidity, mortality and quality of life [3,4]. In addition to re-
storing the microcirculation, cardioprotection and structural regenera-
tion remain important in the treatment of ACS.
This article will discuss effective therapies and feasible catheter in-
terventions using the back door of the heart for myocardial protection
before, during and after the ischemic insult, particularly in the early re-
perfusion period.2. The origin of coronary sinus interventions
The coronary venous route to access deprivedmyocardium and thus
the obstructed microcirculation has a long history, beginning with
retroperfusion of arterial blood in the late 19th century and progressing
to the development of pressure-controlled intermittent coronary sinus
occlusion (PICSO) in the 1980s (Fig. 1) [5–7]. Although there is little
doubt that cardiac veins are useful access routes to jeopardizedmyocar-
dium, few concepts have progressed to clinical development. The
coevolution of interventional cardiology and cardiac surgery hindered
widespread applications of coronary sinus interventions (CSI). Howev-
er, the recent availability of novel interventional technologies has
reversed this trend and revived interest in CSI.
The concept of PICSO, which uses the coronary sinus pressure for
termination of obstructing venous ﬂow in contrast to ﬁxed timed
ICSO, has recently been further developed using new technology.
There are abundant data on myocardial salvage in experimental
ischemia as well as in patients with lysis therapy during or following
ischemia as well as reperfusion [8,9]. Clinical data also support the use
of PICSO in patients after global ischemia and in heart failure patients
[6,10,11]. Recently presented data detail the application of PICSO during
primary PCI in the early reperfusion period [12,13].
The primary aim of coronary sinus interventions was
retroperfusion of arterial blood to the myocardium, but preclinical
and clinical data have suggested other beneﬁcial effects, primarily
redistribution of ﬂow towards underperfused zones and subsequent
washout as well as offering the potential to revive regenerative path-
ways, ultimately restoring structural integrity. The ﬁrst clinical ap-
plication of the concept of using the coronary sinus to access
ischemic myocardium was in the 1940s [14]. A series of pathophysi-
ologic studies enhanced understanding of the reaction to elevated
pressure in cardiac veins as well as reﬂexes originating from the
endocardium close to the oriﬁce of the coronary sinus [15,16]. Fur-
ther studies showed the effects of coronary sinus occlusion tech-
niques on the behavior of the coronary microcirculation [17].
Corday and Meerbaum [18,19] developed interventional
retroperfusion methods such as synchronized retroperfusion (SRP)
and applied them clinically, forcing arterial blood retrograde via a
catheter system during diastole into the ischemic microcirculation
(see video 1) [20]. Further research was halted following a combina-
tion of ambivalent results, unstable technology and the development
of alternatives. Boekstegers reﬁned the retroperfusion technology
using a selective perfusion technique with subsequent suction that
showed positive results in the clinical setting [21,22]. Meerbaum
achieved retrograde lysis of coronary artery thrombus by coronary
venous streptokinase administration [23]. In early clinical studies,
pICSO (pressure observed intermittent coronary sinus occlusion
without automatic closed loop, but observer control of pressure in-
crease) was also able to enhance clot lysis signiﬁcantly, even when
given intravenously (p b 0.05) as compared to controls (Fig. 2) [8].
In addition, retroinfusion has been employed in stem cell research
and gene therapy, showing favorable results when compared to
other delivery routes [24,25].3. The importance of pressure control during coronary sinus
occlusion
Coronary sinus occlusion (CSO) techniques such as ICSO/PICSO and
the Banai stent [26] are based on changes in the pressure and ﬂow rela-
tions in the normal and ischemic heart. During coronary sinus occlusion,
redistribution of ﬂow within the venous compartment allows access to
deprived perfusion zones. During temporal occlusion as seen in ICSO/
PICSO procedures, a phase of washout follows the ﬁlling of the venous
compartment (see videos 2 and 3). In contrast, the Banai stent results in
a chronic elevation of coronary venous pressure and may lead to severe
side effects on coronary circulation including restrictions in venous ﬂow
and permanent reorganization of the venous outﬂow pattern [27,28].
During ICSO, the temporary occlusion of the coronary sinus (which
collects about 70% of the myocardial outﬂow) induces a redistribution
of venous blood and plasma-dense ﬂuid from normally perfused terri-
tories into underperfused areas, such as severe atherosclerotic coronary
arteries and in ACSwith additional thrombus burden. The temporary in-
crease of venous pressure in the coronary sinus induces a continuous
rise and fall of pressure gradients in the microcirculatory bed, clearing
debris and eliminating metabolic waste (Fig. 3) [6,29]. Reactive buffer
systems and the action of osmotic, ionic and, most importantly, me-
chanical forces squeezing blood into the occluded microcirculation, re-
duce the area of the no reﬂow zones. Coronary sinus occlusion
pressure reaches a systolic plateau resulting from the squeezing action
of myocardial contraction. Since redistributed blood ﬂow needs time
to ﬁll the venous compartment, these systolic pressure peaks rise con-
stantly, reaching a plateau after several seconds. During pICSO and
PICSO, this plateau level signals the reopening of venous drainage and
enables optimal redistribution of venous blood (Figs. 4, 5). The pressure
in the occluded coronary artery ﬂuctuates according to the pressure in
the coronary sinus, and the arterial pressure decreases during coronary
sinus release.
Several CSI techniques have undergone investigation. Animal research
by Lazar et al. showed that PICSO was superior to IABP and that a combi-
nation of both methods enhanced the anti-ischemic effect during urgent
surgical revascularization [30–32]. The antiarrhythmic effects of pICSO
have also been observed in animals [33]. More recently, the historic con-
cepts of ICSO and pICSO have been replaced by PICSO [11].
Currently the applications of PICSO have focused on ACS. In an ex-
perimental animal study, Jacobs et al. found that PISCO performed dur-
ing reperfusion signiﬁcantly enhanced myocardial salvage and
postulated that PISCO may decrease heart rate by a reﬂex mechanism
that is mediated by vagal afferents [34]. A clinical study, the Prepare
RAMSES trial (reperfusion after acute PCI in myocardial infarction and
coronary syndromes: efﬁcacy and clinical signiﬁcance), which aimed
to further analyze the salvage potential of this method, has recently
been completed. This study followed the ﬁrst-in-man study using new
technology [12]. Prepare PISCO included 15 patients with stable angina
scheduled for PCI of the left anterior descending artery (LAD). Balloon
occlusion of the LAD was performed twice, once with and once without
PICSO and lasting maximally 3 minutes each, to document the effect of
PICSO on coronary sinus pressure and LAD wedge pressure. PICSO re-
sulted in a marked increase in coronary sinus pressure with no device-
related adverse events reported [11]. In a recently presented study of
32 heart failure patients undergoing resynchronization therapy, PICSO
was performed on 8 patients for 20 minutes versus 24 controls. At
5 year follow-up, themetabolic, biochemical andmolecular changes in-
duced indicated that PICSO has regenerative potential beyond its acute
effect on myocardial ischaemia [35].
In order to realize the full potential of this intervention, questions re-
main regarding the application of PICSO in ACS. There is also need for
additional data to optimize the time window of PICSO to prevent/re-
verse reperfusion injury, to explore the potential to treat different ische-
mic perfusion territories and reduce the volume of obstructed
microcirculation. Although early and recent clinical results are
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Fig. 2. Timeline from symptom onset to reperfusion. The application of about 1 hour of PICSO resulted in a signiﬁcant shorter lysis time indicating better washout of the obstructed
microcirculation. Time points: Onset of pain; AD admission in the hospital, CL admission in the Cath Lab, at the time of PICSO start the lytic agent was given [reprinted from 8,9].
Fig. 3. Thermograms of coronary artery ligation in a canine model of acute ischemia.
A: normal perfusion, B, C: LAD occlusion; D: LAD occlusion and occlusion of the coronary
sinus. E:Washout during coronary sinus release. F: area of underperfusion (risk zone). Re-
distribution of venous blood towards underperfused areas (cold depicted in blue) through
retroperfusion of warm blood during CS occlusion. Thermograms—used for video attach-
ment [reprinted from the coronary sinus library Vol 6.] www.coronarysinus.com.
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matched trial to establish clinical signiﬁcance.
However, there are major limitations associated with analyzing
myocardial salvage in PICSO. It is known that PICSO interferes with
edema formation and increases the energy in border zones by vasodila-
tation of the microcirculation [33,36,37]. These ﬁndings demonstrate a
reduction in the perfusion deﬁcit and therefore reduce the evidence
measured by magnetic resonance imaging (MRI), since it detects
edema, which is claimed to be washed out, and positively inﬂuenced
by PICSO. Myocardial salvage is assessed by MRI several days after the
acute event and therefore includes PICSO effects on the area at risk,
since deprived perfusion zones are normally measured experimentally
before therapy starts. Therefore MRI data in PICSO research might
blunt positive PICSO effects, reducing the perfusion deﬁcit and enhanc-
ing washout. These effects of PICSO should be taken into account since
recent data emphasize the importance and prognostic values of early
changes in ischemic/reperfused microcirculation [38,39].
Stoller and colleagues reported that the reduction of ischemia in pa-
tients treatedwith brief ICSOperiods depends on collateralﬂow [10]. Var-
iable levels of effectiveness of ICSO have been observed and seem to be
dependent on the location of the balloon within the coronary sinus and
therefore the amount of redistributed blood as well as the optimization
of the pressure increase and cycling. A 2004 study on a sheep model
showed that optimal timing signiﬁcantly improves the effectiveness of
the method [40]. However, the ﬁxed timings in ICSO occlusion/release
cycle pattern prohibit optimal redistribution of blood, a limitation that
has been demonstrated in several studies (see also Figs. 5,6) [41–43].
Inadequate duration of the coronary sinus occlusion release leads to
an insufﬁcient retroperfusion/drainage of the coronary sinus and hence
decreases coronary artery inﬂow rather than resulting in washout and
hyperemic response (Fig. 5). The unadjusted ﬁxed ICSO approach is un-
able to correct according to changes in CSP dynamics. Therefore an au-
tomatic closed loop method adapting to the dynamics of individuals
was developed [44–50]. In the majority of studies, pressure control
was achieved by continuous observation and immediate, but observer
controlled adjustment of pressure dynamics by the investigator
(pICSO). A closed loop system for coronary sinus occlusion has been
established that optimizes the beneﬁcial effects of PICSO [51]. The
PICSO cycle adapts instantly (beat to beat) according to the physiologic
state of the heart. Several parameters must be optimized in a PICSO in-
tervention. In order to ensure sufﬁcient coronary drainage, the release
phasemust be long enough to allow the next occlusion phase to be trig-
gered by the end of the peak of hyperemic coronary arterial ﬂow, which
can be detected by observing venous ﬂow (see Fig. 5). In addition, the
occlusion phase must be set to ensure that the systolic coronary sinuspressure reaches a pressure plateau [51]. Further developments have
led to the implementation of proprietary algorithms used in the
PICSO® Impulse System (Miracor Medical). These calculate the time of
occlusion of the venous drainage via the coronary sinus versus the
Fig. 4. Schematic of coronary venous ﬂow redistribution in deprived perfusion zones by PICSO. Note that collateral ﬂow from uncompromised coronaries facilitated by vasodilatation of
vasoactive molecules produced by PICSO enters the border zones and improve perfusion as well as metabolism in these areas. There is a concomitant increase of the coronary sinus
pressure, reaching a systolic plateau after a few seconds, and with a delay the postocclusive arterial pressure shows a synchronous increase. Diastolic pressures also increase according
to the volume increase in the coronary sinus.
Fig. 5.Mean arterial inﬂow (CXF) and great cardiac vein ﬂow (GCV) in relation to coronary
sinus pressure during CS occlusion. Note the hyperemic venous ﬂow indicates a surplus of
washout. The negative ﬂow during occlusion depicts retroperfusion. Note that pressure con-
trol in the coronary sinus is necessary to prevent permanent coronary inﬂow reduction.With
pressure control mean coronary ﬂow remains unchanged due to the “hyperemic response”
during coronary sinus occlusion release [reprinted fromMohl et al., 2005 40].
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pressure dynamics sensed over the ﬂuid-ﬁlled line of the catheter.
Variations in coronary sinus dynamics can also be used as diagnostic
parameters [50]. Fig. 6 shows CSPdynamics aswell as the rapid pressure
increase following the opening of the coronary artery is opened in an
ovine model [29]. This was corroborated in a clinical evaluation of
pICSO during the early reperfusion period. As soon as the bypass grafts
were opened, the rise time in CSP shortened and systolic pressure in-
creased signiﬁcantly, thus reﬂecting surplus of myocardial inﬂow [29].
This shows the importance of immediate response to the occlusion/re-
lease cycles during PICSO.
4. Optimization of PICSO therapy
In order to optimize PICSO therapy, the position of the occluding bal-
loon redirecting blood in relation to side branches of the coronary sinus
is of outmost importance. Exact positioning in an optimal region of the
coronary sinus not only requires expertise, but is also a prerequisite of
the effectiveness of the PICSO procedure. The easiest way to access the
coronary sinus is the left jugular, subclavian or brachial vein. Since a
routine anticoagulation regimen is used in ACS and to minimize the
risk of bleeding, central venous punctures are avoided in several centers
endorsing peripheral veins. The femoral approach has been extensively
used and results in favorable catheterization times [11]. The balloon
catheter is positioned into the so-called “silent zone” of the coronary
sinus (see video 4). Infrequently, an obstructing valve at the coronary
sinus oriﬁce hampers the positioning of the catheter within the silent
zone of the great cardiac vein.
It is also important to stabilize the catheter system against the force
of the outﬂowing blood, especially during the hyperemic response in-
creasing the venous velocity (Fig. 7A, B). The pressure within thepneumatic balloon catheter is monitored, avoiding any excessive force
on the vessel wall and allowing maximal safety. Since the oriﬁce of the
coronary sinus is covered by endocardium and contains nerve endings,
reﬂexes such as hypotension and bradycardia have been observed in an-
imals [15,16]. The squeezing action of the heart creates the pressure
Fig. 6. CSP dynamics: note the sudden increase of pressure in the coronary sinus after
opening of an experimental coronary artery occlusion in sheep making instant regulation
of occlusion/release cycling necessary.
Fig. 7. A. Corrosion cast of the human coronary sinus. Note the area of positioning of the
balloon and the incoming veins from the lateral aspect of the heart (same position as in
the angiogram). B.Optimal positioning in the great cardiac vein. Note that successful redis-
tribution ofﬂow is only possible if the catheter position is proximal tomajor veins draining
blood from the lateral wall.
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therefore important to collect as much inﬂow as possible from veins
draining into the occluded section of the coronary sinus. The rate of
rise gives an estimate of the capacity to be ﬁlled by retroperfused
blood and is a summation of the venous compartment and the coronary
microcirculation deprived from normal circulation. Epicardial ﬂow into
the deprived coronary vasculature and subsequent washout during the
release phase therefore reduces the so-called ‘no reﬂow’ zones that are
present in patients with ACS and allows a shift of blood towards the en-
docardium (Fig. 4).
5. The salvage potential of PICSO
The signiﬁcance of myocardial salvage by ICSO has been established
in a meta-analysis of 7 experimental trials comprising 125 test animals
that showed an inverse relationship between achieved (developed)
coronary sinus systolic pressure, (i.e. occlusion duration and elevation
of the coronary venous systolic pressure per minute multiplied by the
application times of ICSO) and infarct size [52]. The so-called “dose de-
pendence” between optimized ICSO therapy and salvage has been doc-
umented in different species and different durations of ischemia [52].
Syeda et al. reported a signiﬁcant reduction in infarct size of 29.3% in
the pICSO group compared to the control group (p b 0.001; 95% conﬁ-
dence interval,−40.9 to−17.7), which correlated to the achieved (de-
veloped) coronary sinus pressure increase per minute (r = −0.92;
p b 0.007) [52]. This dose-dependency has been recently conﬁrmed by
the Prepare RAMSES study, which showed a signiﬁcant correlation
(r = 0.70, p = 0.008) in reduction in infarct size and the cumulated cor-
onary sinus pressuremodulation over time [53]. This has led to the devel-
opment of an algorithm by Miracor Medical Systems that automatically
calculates the PICSO quantity applied. The quantity is calculated as:
PICSO Quantity
¼
Xn¼Total PICSO Cycles
n¼1
sCSPPn−dCSPPnð Þ  sCSPPn−CSPDAnð Þ  IHTnð Þ
(Balloon inﬂation hold time)× (mean systolic coronary sinus pressure
plateau–mean coronary sinus pressure during deﬂation)× (mean systol-
ic coronary sinus pressure plateau –mean diastolic coronary sinus pres-
sure plateau), summed over the complete PICSO procedure and
expressed in [mm Hg]. It therefore reﬂects the magnitude of coronary
sinus pressure modulation during the complete PICSO procedure.
The meta-analysis by Syeda et al. analyzing different experimental
ischemia protocols showed that additional retroperfusion of arterial
blood during ISCO was found to increase salvage by around 10%, but
dose dependence data showed that the amount of blood retroperfusedhad an inverse correlation to salvage (r=−0.97; p b 0.004), indicating
a counterproductive engorgement of the coronary vasculature. There-
fore, redistribution of venous ﬂow together with periodic washout of
metabolites, rather than additional arterial infusion and perfusion, is re-
sponsible for myocardial salvage [50,54,55].
The relationship between the hemodynamic force of periodic eleva-
tion of coronary venous pressure on jeopardized myocardium and sal-
vage has only recently been appreciated because historically, the
scientiﬁcmainstreamassociated beneﬁcial effects of CSI andmyocardial
salvage with delivery of oxygenated blood. Salvage never occurs in
Krogh-like diffusion cylinders aroundmajor “arterialized” retroperfused
cardiac veins, but rather in border zones of deprived myocardium,
therefore it is very unlikely that retroperfused oxygen is the benefactor
in CSI. On the contrary, it is currently believed that redistribution of ve-
nous blood into the center of ischemia and washout, thus maintaining
basal metabolism as well as vasodilation, collateral ﬂow and improved
perfusion of the border zone leading to increased energy storage is the
main factor of salvage in CSI (see videos 5,6) [37,56].
Clinical data onmyocardial salvage and pICSO are limited to applica-
tions combinedwith lysis therapy and date back to the early clinical tri-
als of CSI [7]. However, long term clinical trial data are available, which
should be corroborated during reperfusion by PPCI in current clinical
trials [9]. Although these historical studies have employed primitive
technology and observer limited pICSO, clinical experience has
Fig. 8. A. Comparison of time to ﬁrst MACE (major adverse cardiovascular event) in a
randomized trial of pICSO in ACS and lysis. Note the signiﬁcant difference between
pICSO and control groupwhichwas observable after 5 years follow up (p b 0.001) indicat-
ing improvements beyondmyocardial salvage [reprinted from9]. B. Hazard function of the
randomized trial in ACS and lysis+/−pICSO after adjustment of differences in reperfusion
time. There is a 96% reduction of the risk for reinfarction (95% conﬁdence interval: 61%–
99%) in patients treated by pICSO compared to control patients and an 86% reduction of
the risk to suffer major adverse cardiac events (MACE) (95% conﬁdence interval: 48%–
96%) in patients treated by PICSO compared to control patients [9]. Major adverse cardiac
event (MACE) free survival was evaluated by means of a Cox hazard regression model
using a 95% conﬁdence interval [reprinted from66]. Note that there is a strong relationship
between restenosis and MACE, the Hazards ratio is 24 (per 25% stenosis), and conﬁdence
limits are 1.86–312 (p=0.0149). Adjusting for restenosis, the relative risk of PICSO com-
pared with control was 0.11 (0.03, 0.40), meaning that the risk for MACE was 9 times
higher for the control group than for the PICSO group [9].
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surements in patients with a lysis protocol with and without PICSO
showed signiﬁcantly less total creatine kinase (CK) release than that
of the control group, an important ﬁnding since CK is a prognostic indi-
cator following acute myocardial infarction (MI) [57]. Infarct size
assessed at 30 days after onset of symptoms was signiﬁcantly smaller
for the PICSO group compared with the control group [9]. Although CS
catheter placement required additional treatment time (mean time to
insert a balloon catheter into the CS was 11 ± 4 min) the period to
the completion of reperfusion in the infarct-related artery from the
initial administration of thrombolysis agents was signiﬁcantly shorter
for the PICSO group (28 ± 12 min) than for the control group
(41 ± 18 min, p = 0.014) (Fig. 2). The reduced procedure time in the
PICSO group resulted from enhanced clearing of the microcirculation
and even the site of coronary occlusion from thrombus (as seen by
Meerbaum in animal models [23]). A left ventriculogram at 30 days
after MI showed that the PICSO group had signiﬁcantly smaller
abnormally contracting segments (21.4 ± 16.5%) than the controlgroup (31.9 ± 10.6%; p b 0.05). The global ejection fraction, however,
did not differ signiﬁcantly among groups.
Surprisingly, 5-year follow up showed results on risk reduction to
suffer from re-infarction or major cardiac events: 96% risk reduction
for re-infarction (95% CI: 61%–99%), 86% risk reduction for major ad-
verse cardiac events (MACE) (95% CI: 48%–96%) after PICSO. Freedom
from major adverse cardiac events was 82% for the PICSO group but
only 23% for the control group (Fig. 8A, B). These results are noteworthy
since they show superiority even against recent analysis of STEMI by Pe-
dersen et al. [58] even after risk adjustments for differences in times to
reperfusion and correcting for residual stenosis in the culprit vessel after
30 days. In context withWeigel's ﬁndings on upregulation of vasoactive
and cardioprotective molecules in experimental studies applying PICSO
and recent clinical ﬁndings by Kusmic supporting the clinical effective-
ness of upregulation of HO-hemeoxygenase, PICSO unfolds a second im-
portant mechanism, namely support of regenerative efforts of the
myocardium in jeopardy [37,59]. These discoveries have been a turning
point in the knowledge of the basicmechanism of PICSO and have led to
the development of the hypothesis “embryonic recall”, claiming that
PICSO interferes with molecular cascades during infarct healing and
might initiate structural recovery beyond salvage.
Historical data for PICSO in ACS are only available for intervention in
the late ischemic time, but before reperfusion. Recent advances enable in-
tervention in the early reperfusion period. Itmay be possible to commence
PICSO when passing the guide wire to reopen the coronary occlusion be-
fore treating the residual stenosis. Furthermore, the existing relationship
between cellular damage and enzyme leakage during PICSO and intensi-
ﬁed washout relates to better preservation of regional function [29].
Recently van de Hoef et al. compared matched controls with 30 pa-
tients with acute coronary syndromes treated with PPCI and additional
90 minutes of PICSO in the reperfusion period. He conﬁrmed additional
salvage (baseline versus 4 months) in the PICSO group compared to
matched controls measured by MRI (41,6+/−8,2% vs. 27,7+/−9,9%
p b 0.04) [53].
6. Molecular basis of structural regeneration by PICSO
Supported by the paradigm change mentioned above, PICSO can be
envisioned as the combination of two independent mechanisms: access
to deprivedmyocardiumby clearing the obstructedmicrocirculation and
its regenerative potential (Fig. 9). In order to understand the regenera-
tive process, it is necessary to revisit historic data. A report of the Beck's
procedure (permanent occlusion of the venous outﬂowwith subsequent
arterialization of the venous coronary vascular compartment) on long-
term histologic changes of ischemicmyocardium describedmany vascu-
lar channels distal to the occluded artery [60], which indicates
neoangiogenesis. It has been suggested that pulsatile pressure might be
the origin of these changes [61], leading to the “embryonic recall”
hypothesis, formulated to elucidate the mode of action of PICSO [62].
The “embryonic recall” hypothesis postulates that PICSO directly in-
terferes with the healing process after MI and the development of
neoangiogenesis in the myocardial infarct zone. Under normal circum-
stances, the contribution of neoangiogenesis to the infarct bed capillary
network is insufﬁcient to enable the tissue growth required for contrac-
tile compensation, but PICSO (by its mechanotransduction effect) initi-
ates developmental processes in the adult heart. During cardiac
development, molecular signals are needed to induce structural matu-
ration. The ﬁrst cardiac pulsations in the primitive heart tube are sensed
via endocardial cells and as a result, molecular pulses initiate structural
development of the myocardium in the embryo. In this hypothesis,
PICSO initiates the same molecular pulses in the adult myocardium
leading to regeneration.
The reopening of an epigenetic window into the morphogenetic
pathways of the developing heart for cell survival, including pathways
such as mechanotransduction and activation of endothelium, is well
established [63]. Since it has been suggested that mechanical factors
Fig. 9. Effects and claims of PICSO in this graph and the initialmode of action ofmechanotransduction and redistribution ofﬂow are summarized leading to the two independent principles
of PICSO namely salvage and regeneration & cardioprotection [modiﬁed from 67].
43W. Mohl et al. / Cardiovascular Revascularization Medicine 16 (2015) 36–46play amajor role in coronary angiogenesis as well as sculpturing the de-
veloping heart, a biomechanical intervention should affect myocardial
gene expression. It has been shown that shear stress on the endotheli-
um during ischemia induces signaling pathways, leading to the forma-
tion of collaterals via pressure and ﬂow gradients within the
microcirculation and consequently to increased shear stress. Periodic
venous pressure elevation by PICSO therefore results in known effects
of retroperfusion such as myocardial salvage, as well as having angio-
genic effects. The upregulation of vasoactive (adenosine, vascular endo-
thelial growth factor [VEGF] and its receptor) aswell as cardioprotective
(heme oxygenase [HO])molecules has been observed in animal studies,
supporting this hypothesis [37,56,64,65].
Themolecular cascade induced by themechanical force on endothe-
lium has been studied on two functionally interrelated, proangiogenic
genes in porcine myocardium: HO-1, an anti-atherosclerotic molecule
also known to be involved in vasodilation, and VEGF, which has
shown recently to be an important support leading to better cardiac
function in 4 week follow up after experimental infarction [59,66]. It is
anticipated that themicrocirculatory stretch induced by PICSO is associ-
ated with the upregulation of HO-1 and VEGF mRNA, two markers
expressed by the activated endothelium,whereas the ischemic pathway
via hypoxia-induced factor (HIF) activity remains unchanged [67]. This
upregulation of pro-angiogenetic molecules have been observed in re-
mote zones as well as in border zones and also to some extent in ische-
mic zones. It is noteworthy that that VEGF/VEGF2 and their receptor
proteins were markedly upregulated in myocardial cells in the remote
zone but not in the coronary sinus blood during experimental coronary
artery occlusion in pigs [35,65,66,68–72]. These are signiﬁcant ﬁndings,
since soluble VEGF in peripheral bloodmay be a prognostic indicator for
restenosis after stenting [70].Table 1
Embryonic recall molecules and their references involved both in development and also
upregulated in regeneration as well as through PICSO.
Molecules upregulated during
development
Regenerative molecules upregulated by
PICSO
VEGF, FGFs [71] VEGF [37]
KLF2 [72] HO-1 [37]
IL-6 [73] IL-6 [74]7. Future developments
Although PICSOmight be best applied immediately before PPCI, there
remains a need to investigate the effects of a longer timewindowof PICSO
application in the early reperfusion period. Reperfusedmyocardiumwith
cell death, (i.e. apoptosis and necrosis) cell signaling and cell migration isa potential analogue to a lizard's blastema formation combining growth
signals with dedifferentiation of cells inducing structural rescue, which
cannot be established inmammalian hearts without additional regenera-
tive phenomena.Many species able to regenerate in adulthood use a blas-
tema, which is an epigenetically controlled regeneration zone combining
molecular signals from dying and dedifferentiated as well as migrated
cells able to reenter the cell cycle producing structural recovery. It may
be expected that coronary sinus interventions produce similar effects.
Based on our hypothesis and experimental and early clinical ﬁnd-
ings, there is a strong rationale for investigating the potential of PICSO
in heart failure patients. Future clinical research is mandatory to deci-
pher the regenerative potential of PICSO and to further support the hy-
pothesis that a relatively easy coronary sinus intervention can induce
structural regeneration.
8. Conclusion
Clearing microvascular obstruction via cardiac veins has undergone
a resurgence in interest in treating patients with complex high risk in-
terventional procedures as well as in ACS. Tables 1 and 2 highlight the
most important facts in coronary sinus research including experimental
and clinical evidence. Conceptualized decades ago, access to deprived
myocardium has demonstrated beneﬁts during ischemia, which have
been corroborated by preliminary studies in the era of PPCI. Clinical
results indicated that the salvage potential of PICSO is dose dependent,
but that a second threshold dependent effect inﬂuencing structural
regeneration also inﬂuences patient outcome. Activation of venous
Table 2
Concepts of CSI and studies on pICSO/PICSO on myocardial salvage and regeneration.
Studies Major ﬁndings References
Different concepts of coronary
sinus interventions
1. Arterialisation of the coronary
sinus (Beck's procedure)
2. Synchronized retroperfusion
techniques
3. Pressure controlled Intermittent
coronary sinus occlusion techniques
4. Retroinfusion techniques including
retrograde cardioplegia
Claims & ﬁndings: Improved function
in diffuse coronary artery disease,
early ﬁndings in angiogenesis,
improved survival. Many of these
procedures have been applied pre
CABG and interventional cardiology era.
*Presently used concepts:
1. PICSO
2. Banai stent
3. Retrograde cardioplegia
4. Retroinfusion (gene delivery)
[5,7,14,19,21,22,24–26,75]
Mode of action of PICSO 1. Salvage potential 1. Redistribution of ﬂow
towards ischemic areas
2. Washout of toxic metabolits
3. Reducing no reﬂow areas
4. Reopening microcirculation
5. Improved ﬂow in border zones
[33,56,75,76]
2. Regenerative potential 1. Embryonic recall [61,62]
pICSOPreclinical studies on
myocardial salvage and
functional improvement
1. Different species and forms of myocardial
ischemia and reperfusion
2. Jacobs performed the only equivalent
study on PICSO and reperfusion to
modern PPCI in dogs
3. Functional studies CAO in dogs and PICSO
4. Comparison of pICSO with IABP and LVAD
Dose dependent (developed
coronary sinus pressure)
Salvage between 50%
(total LAD occlusion over
6 hours and 30% in meta-analysis;
note that additional delivery of
arterial blood improved the
quantity of salvage however
there was a reversed relationship
between salvage and the amount
of retropefused blood). Equivalent
to PPCI PICSO study showed
about 30% salvage.
Regional functional improvement
[54,5,30,32,34,52,55]
Preclinical studies proposing
structural regeneration
Study in swine and coronary
artery occlusion
Increase in angiogenetic and
vasoactive molecules
(Ho-hemoxygenase, VEGF,
Adenosine) supporting the
claim perfusion increase and
increase in high energy
phosphates in ischemic borderzones
[37,56,64]
First in man Randomized study of pICSO during
the early reperfusion period in
CABG (15 pICSO vs. 15 controls)
Functional improvement of severely
depressed regional function, trend
towards clinical improvements
(less infection, shorter ICU stay,
less catecholamine support
[29]
Randomized clinical study
on pICSOIn ACS
and lysis therapy
15 pICSO vs. 15 controls during lysis 30% increase of salvage
Earlier clot lysis (see Fig. 2)
[8]
Long-term follow
up of study above
5 year follow up of Komamura's
study cited above
Signiﬁcant reduction of MACE and
re-infarction (see Fig. 8A, B)
[9]
pICSO in heart failure 8 patients with 20 minutes PICSO
during resynchronization
therapy vs. 24 controls
No changes in short term
hemodynamics and metabolism
[35]
Long term follow
up pICSO in heart failure
ATOS I study retrospective controlled
trial in heart failure patients
Reduction of mortality Molecular
insight in mode of action of PICSO
(hypothesis of embryonic recall) see ﬁgure
[35]
New generation of
PICSO technology
1. Prepare PICSO
2. Prepare Ramses
1. Increase in postocclusive coronary
artery pressure trend towards
reduction of ST segment elevation
2. Dose dependent (CSP quantity)
trend towards decrease of infarct size
[12,13]
44 W. Mohl et al. / Cardiovascular Revascularization Medicine 16 (2015) 36–46endothelium by the hemodynamic force of venous blood initiates mo-
lecular cascades similar to developmental processes, leading to the pos-
sibility that limiting ischemic jeopardy and regaining structural
integrity might be a realistic goal for the interventional cardiologist.Funding
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